With cash in its coffers from last year's sale of Domantis Ltd. to GlaxoSmithKline plc, Peptech Ltd. is buying out EvoGenix Ltd. for A$156 million (US$128.6 million), a 33 percent premium to the last trading price, in a bid to create yet another formidable antibody player. (BioWorld Today)

Cancer-focused AVEO Pharmaceuticals Inc.'s rare balance between antibody and small-molecule discovery bagged $53 million in a Series D financing that leaves the firm with enough cash to last "a little bit short of two years," said Tuan Ha-Ngoc, president and CEO. (BioWorld Today)